Skip to main content
. Author manuscript; available in PMC: 2019 Oct 18.
Published in final edited form as: Angew Chem Int Ed Engl. 2019 Jul 10;58(40):14066–14080. doi: 10.1002/anie.201814098

Figure 6.

Figure 6.

Use of UCMSs-MC540-TF nanovaccines to enable the integration of PDT and immunotherapy. UCNPs (β-NaYF4:20%Yb,2%Er) encapsulated by porous silica were mixed with merocyanine 540 (MC540) and antigens (tumor cell fragment). The resultant UCMSs-MC540-TF were given to a mice model. Upon irradiation of 980 nm NIR light, PDT was triggered to form tumor-associated antigens, which activated the maturation of dendritic cells. As a result, effector T cells were released to trigger immunotherapy for more effective cancer therapy.[64]